Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Review ArticleReview Article
Open Access

CAR T-cell therapy in acute myeloid leukemia

Alhomidi Almotiri
Saudi Medical Journal October 2024, 45 (10) 1007-1019; DOI: https://doi.org/10.15537/smj.2024.45.10.20240330
Alhomidi Almotiri
From the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Kingdom of Saudi Arabia.
MSc, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alhomidi Almotiri
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    - The timeline of major developments in chimeric antigen receptor T-cell therapy. CML: chronic myeloid leukemia, CAR: chimeric antigen receptor, CRISPR: clustered regularly interspaced short palindromic repeats, FDA: Food and Drug Administration, cTCR: chimeric T-cell receptor, SLE: systemic lupus erythematosus

Tables

  • Figures
    • View popup
    Table 1

    - Registered clinical trials using chimeric antigen receptor T-cell for acute myeloid leukemia in https://clinicaltrials.gov/ as of 8/3/2024.

    Trial identifiersStudy namesCondition(s)Study typeAntigensPhasesEnrollments†Start datesCompletion datesResponsible partiesStatus
    NCT04033302Multi-CAR T-cell therapy targeting CD7-positive malignanciesAML, T-cell acute lymphoblastic leukemia/lymphoma, NK cell lymphomaInterventionalCD7I/II3020192023Shenzhen Geno-Immune Medical InstituteUnknown
    NCT04762485Humanized CD7 CAR T-cell therapy for r/r CD7+ acute leukemiaAML, T lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemiaInterventionalCD7I/II2020212024The First Affiliated Hospital of Soochow UniversityUnknown
    NCT05377827Dose-escalation and dose-expansion study to evaluate the safety and tolerability of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in patients with CD7+ hematologic malignanciesAML, T-Cell non-Hodgkin lymphoma, othersInterventionalCD7I5420232026Washington University School of MedicineRecruiting
    NCT05995028Universal 4SCAR7U targeting CD7-positive malignanciesAML, T-cell acute lymphoblastic leukemia/lymphoma, NK cell lymphomaInterventionalCD7I3020232026Shenzhen Geno-Immune Medical InstituteRecruiting
    NCT03896854CART-19 T-cell in CD19 positive relapsed or refractory acute myeloid leukemia (AML)AMLInterventionalCD19I/II1520172025Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdRecruiting
    NCT04796441Clinical study of universal CAR-γδT-cell injection in the treatment of patients with relapsed AML after transplantationAMLInterventionalCD19NA2020202022Hebei Senlang Biotechnology Inc., LtdUnknown
    NCT04257175CAR-T CD19 for acute myelogenous leukemia with t 8:21 and CD19 expressionAMLInterventionalCD19II/III1020202024Sheba Medical CenterRecruiting
    NCT05513612Novel CAR-T cell therapy in the treatment of hematopoietic and lymphoid malignanciesAML, B-NHL, othersInterventionalCD19I020202026Shanghai Pudong HospitalWithdrawn
    NCT05388305Universal CAR-γδT cell injection in the AML patientsAMLInterventionalCD19NA3020222023Hebei Senlang Biotechnology Inc., LtdRecruiting
    NCT01864902Treatment of relapsed or chemotherapy refractory CD33 positive acute myeloid leukemia by CART-33 (CART33)R/R AMLInterventionalCD33I/II1020132017Chinese PLA General HospitalUnknown
    NCT02799680Allogeneic CART-33 for relapsed/refractory CD33+ AMLR/R AMLInterventionalCD33-1220152018The Affiliated Hospital of the Chinese Academy of Military Medical SciencesUnknown
    NCT03971799Study of anti-CD33 chimeric antigen receptor-expressing T-cells (CD33CART) in children and young adults with relapsed/refractory acute myeloid leukemiaAMLInterventionalCD33I/II5220202039Center for International Blood and Marrow Transplant ResearchActive, not recruiting
    NCT05105152PLAT-08: a study of SC-DARIC33 CAR T-cells in pediatric and young adults with relapsed or refractory CD33+ AMLAMLInterventionalCD33I1820212041Colleen Annesley, Seattle Children’s HospitalRecruiting
    NCT04835519Phase I/II study of enhanced CD33 CAR T-cells in subjects with relapsed or refractory acute myeloid leukemiaR/R AMLInterventionalCD33I/II2520212024Beijing Boren HospitalRecruiting
    NCT05672147CD33-CAR T-cell therapy for the treatment of recurrent or refractory acute myeloid leukemiaR/R AMLInterventionalCD33I2720232026City of Hope Medical CenterRecruiting
    NCT05445765Anti-CD33 CAR-T cells for the treatment of relapsed/refractory CD33+ acute myeloid leukemiaR/R AMLInterventionalCD33I10CD3320222024iCell Gene TherapeuticsNot yet recruiting
    NCT05473221Evaluate the safety and efficacy of CD33 CAR-T in patients with R/R AMLAMLInterventionalCD33I2020222025Zhejiang UniversityNot yet recruiting
    NCT05945849CD33KO-HSPC infusion followed by CART-33 infusion(s) for refractory/relapsed AMLR/R AMLInterventionalCD33I1620242044University of PennsylvaniaNot yet recruiting
    NCT05984199Donor-derived anti-CD33 CAR T-cell therapy (VCAR33) in patients with relapsed or refractory AML after allogeneic hematopoietic cell transplantR/R AMLInterventionalCD33I/II2420232026Vor BiopharmaRecruiting
    NCT04351022CD38-targeted chimeric antigen receptor T-cell (CART) in relapsed or refractory acute myeloid leukemiaR/R AMLInterventionalCD38I/II2020172023The First Affiliated Hospital of Soochow UniversityUnknown
    NCT05239689Clinical study of CD38 CAR-T cells in the treatment of hematological malignanciesAMLInterventionalCD38I3620222024Zhejiang UniversityRecruiting
    NCT05442580CART-38 in adult AML and MM patientsAML, MMInterventionalCD38I3620232041University of PennsylvaniaRecruiting
    NCT04662294CD 70 CAR T for patients with CD70 positive malignant hematologic diseasesAML, NHL, MMInterventionalCD70I10820212027Zhejiang UniversityRecruiting
    NCT04692948TAA6 cell injection in the treatment of patients with relapsed/refractory acute myeloid leukemiaAMLInterventionalCD276NA520192023PersonGen BioTherapeutics (Suzhou) Co., Ltd.Unknown
    NCT05731219UTAA06 injection in the treatment of relapsed/refractory acute myeloid leukemiaR/R AMLInterventionalB7-H3 (CD276)I1820222025PersonGen BioTherapeutics (Suzhou) Co., Ltd.Recruiting
    NCT05722171Clinical study of UTAA06 injection in the treatment of relapsed/refractory acute myeloid leukemiaR/R AMLInterventionalB7-H3 (CD276)I1020222024PersonGen BioTherapeutics (Suzhou) Co., Ltd.Recruiting
    NCT03585517Safety and efficacy evaluation of IM23 CAR-T cells (IM23CAR-T)AMLInterventionalCD123I1020182020Beijing Immunochina Medical Science & Technology Co., Ltd.Completed
    NCT02159495Genetically modified T-cell immunotherapy in treating patients with relapsed/refractory acute myeloid leukemia and persistent/recurrent blastic plasmacytoid dendritic cell neoplasmAML, blastic plasmacytoid dendritic cell neoplasmInterventionalCD123-3120152024City of Hope Medical CenterActive, not recruiting
    NCT03114670Donor-derived anti-CD123-CART cells for recurred AML after Allo-HSCTAdult AMLInterventionalCD123-2020172021Affiliated Hospital to Academy of Military Medical SciencesUnknown
    NCT03190278Study evaluating safety and efficacy of UCART123 in patients with relapsed/refractory acute myeloid leukemia (AMELI-01)R/R AMLInterventionalCD123-6520172024Cellectis S.A.Recruiting
    NCT03556982CART-123 for relapsed/refractory scute myelocytic leukemia (AML)R/R AMLInterventionalCD123I/II1020182020The Affiliated Hospital of the Chinese Academy of Military Medical SciencesUnknown
    NCT04265963CD123-targeted CAR-T cell therapy for relapsed/refractory acute myeloid leukemiaAMLInterventionalCD123I/II4520192024Chongqing Precision Biotech Co., LtdRecruiting
    NCT04272125Safety and efficacy of CD123-targeted CAR-T therapy for relapsed/refractory acute myeloid leukemiaAMLInterventionalCD123I/II4020192024Chongqing Precision Biotech Co., LtdRecruiting
    NCT05949125Dose-escalating trial with Allo-RevCAR01-T cells in combination with CD123 target module (R-TM123) for participants with selected hematologic malignancies positive for CD123AMLInterventionalCD123I3720242025AvenCell Europe GmbHRecruiting
    NCT04318678CD123-directed autologous T-cell therapy for acute myelogenous leukemia (CATCHAML)AML, MDS, B-ALL, T-ALL, BPDCNInterventionalCD123I3220202025St. Jude Children’s Research HospitalActive, not Recruiting
    NCT04678336CD123 redirected T-cells for AML in pediatric subjectsR/R AML, pediatric AMLInterventionalCD123I1220212036University of PennsylvaniaActive, not Recruiting
    NCT04884984Anti-CLL1 CAR T-cell therapy in CLL1 positive relapsed/refractory acute myeloid leukemia (AML)AMLInterventionalCLL1I/II2020172024The First Affiliated Hospital of Soochow UniversityRecruiting
    NCT05467202Evaluate the safety and efficacy of CLL1 CAR-T in patients with R/R AMLAMLInterventionalCLL1I2020222025Zhejiang UniversityNot yet recruiting
    NCT04219163Chimeric antigen receptor T-cells for the treatment of AML expressing CLL-1 antigenAMLInterventionalCLL1I/II1820202038Baylor College of MedicineRecruiting
    NCT04923919Clinical study of chimeric antigen receptor T lymphocytes (CAR-T) in the treatment of myeloid leukemiaAMLInterventionalCLL1I10020212024920th Hospital of Joint Logistics Support Force of People’s Liberation Army of ChinaRecruiting
    NCT05252572Clinical study of CLL1 CAR-T cells in the treatment of hematological malignanciesAMLInterventionalCLL1I3620222024Zhejiang UniversityRecruiting
    NCT06128044CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy in patients with relapsed/refractory acute myeloid leukemia (AMpLify)R/R AMLInterventionalCLL1I7020232028Caribou Biosciences, Inc.Recruiting
    NCT06118788Phase I clinical study: BG1805 injection in the treatment of relapsed or refractory acute myeloid leukemiaR/R AMLInterventionalCLL1I2420232025Guangzhou Bio-gene Technology Co., LtdNot yet recruiting
    NCT05023707Anti-FLT3 CAR T-cell therapy in FLT3 positive relapsed/refractory acute myeloid leukemiaR/R AMLInterventionalFLT3I/II520212025The First Affiliated Hospital of Soochow UniversityRecruiting
    NCT05432401TAA05 injection in the treatment of adult patients with FLT3-positive relapsed/refractory acute myeloid leukemiaFLT3-positive R/R AMLInterventionalFLT3I1820222025PersonGen BioTherapeutics (Suzhou) Co., Ltd.Recruiting
    NCT05445011Anti-FLT3 CAR-T cell (TAA05 cell injection) in the treatment of relapsed/refractory acute myeloid leukemiaAMLInterventionalFLT3I1220222027Wuhan Union Hospital, ChinaRecruiting
    NCT03018405A dose escalation Phase I study to assess the safety and clinical activity of multiple cancer indications (THINK)MDS/AML/MMInterventionalNKG2D-/II14620162021Celyad Oncology SAUnknown
    NCT04658004NKG2D CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemiaAMLInterventionalNKG2DI3620212027Zhejiang UniversityNot yet recruiting
    NCT04599543IL3 CAR-T cell therapy for patients with CD123 positive relapsed or refractory acute myeloid leukemiaAMLInterventionalIL3I3620202026Zhejiang UniversityNot yet recruiting
    NCT05266950Safety and efficacy study of CI-135 CAR-T cells in subjects with relapsed or refractory acute myeloid leukemiaAMLInterventionalCI-135I720212025Beijing Boren HospitalRecruiting
    NCT04803929Clinical study of anti-ILT3 CAR-T therapy for R/R AML (M4/M5)R/R AML (M4/M5)InterventionalILT3I2520212026Carbiogene Therapeutics Co. Ltd.Recruiting
    NCT05463640Evaluate the safety and efficacy of ADGRE2 CAR-T in patients with R/R AMLAMLInterventionalADGRE2I2020222025Zhejiang UniversityNot yet recruiting
    NCT05488132Administration of anti-siglec-6 CAR-T cell therapy in relapsed and refractory acute myeloid leukemia (rr/AML)R/R AMLInterventionalSiglec-6I/II2020222025Xuzhou Medical UniversityRecruiting
    NCT06197672Chimeric antigen receptor T-cell redirected to target CD4 positive relapsed refractory acute myeloid leukemia (AML) as a bridge to allogeneic stem cell transplantR/R AMLInterventionalCD4I3020242042Indiana UniversityNot yet recruiting
    NCT06281847An adaptive open-label multicentre Phase 1/2 trial, to determine the recommended Phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML001)R/R AMLInterventionalIL-1RAPI/II14320242041Advesya SASNot yet recruiting
    NCT06017258A study of CD371-YSNVZIL-18 CAR T-cells in people with acute myeloid leukemiaAMLInterventionalCD371I620232026Memorial Sloan Kettering Cancer CenterRecruiting
    NCT05016063Dual CD33-CLL1-CAR-T cells in the treatment of relapsed/refractory acute myeloid leukemiaAMLInterventionalCD33/CLL1I3220212023Xinqiao Hospital of ChongqingUnknown
    NCT05248685Optimized dual CD33/CLL1 CAR T-cells in subjects with refractory or relapsed acute myeloid leukemiaAMLInterventionalCD33/CLL1I2020222024Beijing Boren HospitalUnknown
    NCT03795779CLL1-CD33 cCAR in patients with relapsed or refractory, high risk hematologic malignanciesAML, MDS, MPN, CMLInterventionalCLL1/CD33I2020182022iCell Gene TherapeuticsUnknown
    NCT05467254Evaluate the safety and efficacy of CLL1+CD33 CAR-T in patients with R/R AMLAMLInterventionalCLL1/CD33I2020222025Zhejiang UniversityNot yet recruiting
    NCT06110208Study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T in r/r AMLR/R AMLInterventionalCLL1/CD38I1820232026920th Hospital of Joint Logistics Support Force of People’s Liberation Army of ChinaRecruiting
    NCT04010877Multiple CAR-T cell therapy targeting AMLAMLInterventionalCLL1, CD33, CD123I/II1020192023Shenzhen Geno-Immune Medical InstituteUnknown
    NCT03222674Multi-CAR T-cell therapy for acute myeloid leukemiaAMLInterventionalMuc1/CLL1/CD33/CD38/CD56/CD123I/II1020172020Shenzhen Geno-Immune Medical InstituteUnknown
    NCT03291444CAR-T cells combined with peptide specific dendritic cell in relapsed/refractory leukemia/MDSAMLInterventionalCD33, CD38, CD56, CD117, CD123, CD34, Muc1I3020172025Zhujiang HospitalRecruiting
    NCT05995041Universal CAR-T cells targeting AMLR/R AMLInterventionalCLL-1, CD33, CD38, CD123I3020232026Shenzhen Geno-Immune Medical InstituteRecruiting
    NCT04766840Donor-derived CAR-T cells in the treatment of AML patientsAMLInterventionalnot shownI920212023Beijing Immunochina Medical Science & Technology Co., Ltd.Unknown
    NCT03473457CAR-T cells therapy in relapsed/refractory acute myeloid leukemia (AML)R/R AMLInterventionalNot shownNA220182020Zhujiang HospitalTerminated*
    NCT04097301Study of CAR T-cell therapy in acute myeloid leukemia and multiple myelomaR/R AML, MMInterventionalCD44v6I/II820192021AGC Biologics S.p.ATerminated∆

    CAR: chimeric antigen receptor, AML: acute myeloid leukemia, NK: natural killer, B-NHL: B-cell non-Hodgkin lymphomas, R/R: relapsed/refractory, NA: not applicable MM: multiple myeloma

    • ↵† The ‘estimated’ enrollment is the target number of participants that the researchers need for the study.

    • ↵* The therapeutic effect was not as expected.

    • ↵∆ Inability to close the study in a clinically relevant time frame.

PreviousNext
Back to top

In this issue

Saudi Medical Journal: 45 (10)
Saudi Medical Journal
Vol. 45, Issue 10
1 Oct 2024
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CAR T-cell therapy in acute myeloid leukemia
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
CAR T-cell therapy in acute myeloid leukemia
Alhomidi Almotiri
Saudi Medical Journal Oct 2024, 45 (10) 1007-1019; DOI: 10.15537/smj.2024.45.10.20240330

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CAR T-cell therapy in acute myeloid leukemia
Alhomidi Almotiri
Saudi Medical Journal Oct 2024, 45 (10) 1007-1019; DOI: 10.15537/smj.2024.45.10.20240330
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • ABSTRACT
    • Introduction
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Harnessing artificial intelligence for infection control and prevention in hospitals
  • Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes
  • The future of personalized medicine in Saudi Arabia
Show more Review Article

Similar Articles

Keywords

  • acute myeloid leukemia
  • CAR T-cells
  • adoptive T-cell therapy
  • chimeric antigen receptor
  • leukemia
  • cancer therapy

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire